Patents by Inventor Ajay Kumar Singh
Ajay Kumar Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938217Abstract: Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.Type: GrantFiled: January 18, 2023Date of Patent: March 26, 2024Assignee: SLAYBACK PHARMA LLCInventors: Rahul Dhulaji Bhise, Ajay Kumar Singh, Mahadeo Vasant Mahadik, Ashish Anilrao Dubewar, Molugu Prashanth Reddy
-
Publication number: 20240090047Abstract: This Application sets forth techniques for managing the cellular connectivity state of a submerged wireless device. The wireless device can include sensors that analyze environmental conditions to determine when the wireless device is (or is not) submerged underwater as well as at what depth the wireless device is submerged underwater. The sensors can also determine different types of aquatic activity in which a user of the wireless device is currently engaged, such as swimming, snorkeling, free diving, and scuba diving. In turn, the wireless device can utilize this information to manage its cellular connectivity state in order to avoid wasteful consumptions of energy. In particular, the techniques enable the submerged wireless device to eliminate any existing cellular connection as well as connection reattempts so long as they are unlikely to succeed. Moreover, the techniques enable the wireless device to execute connection reattempts when they are appropriate and likely to succeed.Type: ApplicationFiled: August 15, 2023Publication date: March 14, 2024Inventors: Ajoy K. SINGH, Ajay kumar S. GUPTA, Prathyusha PALLERLAMUDI
-
Publication number: 20240009188Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: September 15, 2023Publication date: January 11, 2024Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Sandeep JAIN, Hanimi Reddy BAPATU
-
Patent number: 11802112Abstract: The present invention relates to preparation of pyrazoles. This invention further relates to a continuous flow micro-total process system for preparation of celecoxib, a COX-2 selective non-steroidal anti-inflammatory drug, and analogs thereof.Type: GrantFiled: January 27, 2020Date of Patent: October 31, 2023Assignee: Council of Scientific & Industrial ResearchInventors: Srihari Pabbaraja, Ajay Kumar Singh, Vinay Kumar Sthalam
-
Patent number: 11793809Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: November 20, 2020Date of Patent: October 24, 2023Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
-
Publication number: 20230248742Abstract: Stable pharmaceutical compositions are provided, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: ApplicationFiled: April 12, 2023Publication date: August 10, 2023Applicant: SLAYBACK PHARMA LLCInventors: Umangi K. SONI, Prem Prakash SINGH, Hanimi Reddy BAPATU, Praveen Kumar SUBBAPPA, Ajay Kumar SINGH
-
Publication number: 20230234918Abstract: A process for producing diazomethane of Formula 1 (CH2N2), with an automated apparatus is described. A stock solution of N-methyl-N-nitroso amine in an organic solvent is continuously flown and mixed with an aqueous inorganic base at a T-mixer to form a mixture. Then it is passed through a capillary micro reactor at a temperature in a range of 20 to 30° C. to form diazomethane. The mixture is separated into an aqueous layer and an organic layer using a continuous flow micro-separator. The organic layer has 0.1-0.4 M diazomethane. The organic layer is reacted with a carboxylic acid, phenol, an alkyne, an anhydride, a carboxyl metal organic framework (MOF), or MOF coated cotton to form a corresponding ester, a pyrazole, an ether, a diazo ketone, a stable carboxyl MOF or a stable MOF coated cotton fiber.Type: ApplicationFiled: August 24, 2021Publication date: July 27, 2023Inventors: Ajay Kumar SINGH, Srihari PABBARAJA, Deepak Kumar JAISWAL, Dnyaneshwar AAND, Abhilash RANA
-
Publication number: 20230149294Abstract: Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.Type: ApplicationFiled: January 18, 2023Publication date: May 18, 2023Applicant: SLAYBACK PHARMA LLCInventors: Rahul Dhulaji BHISE, Ajay Kumar SINGH, Mahadeo Vasant MAHADIK, Ashish Anilrao DUBEWAR, Molugu Prashanth REDDY
-
Patent number: 11642355Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, as well as methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: GrantFiled: March 16, 2022Date of Patent: May 9, 2023Assignee: SLAYBACK PHARMA LLCInventors: Umangi K. Soni, Prem Prakash Singh, Hanimi Reddy Bapatu, Praveen Kumar Subbappa, Ajay Kumar Singh
-
Publication number: 20220202830Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, as well as methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: ApplicationFiled: March 16, 2022Publication date: June 30, 2022Applicant: SLAYBACK PHARMA LLCInventors: Umangi K. SONI, Prem Prakash SINGH, Hanimi Reddy BAPATU, Praveen Kumar SUBBAPPA, Ajay Kumar SINGH
-
Patent number: 11344858Abstract: The present invention relates to a continuous micro-electro-flow reactor system for ultra-fast, oxidant free, C—C coupling reaction for making symmetrical biaryls and analogs thereof. This invention further relates to the said process for preparation of antiviral drug, daclatasvir of general formula I.Type: GrantFiled: April 1, 2020Date of Patent: May 31, 2022Inventors: Ajay Kumar Singh, Srihari Pabbaraja, Subhash Ghosh, Mahajan Bhushan, Taufiqueahmed Mujawar
-
Publication number: 20220127235Abstract: The present invention relates to preparation of pyrazoles. This invention further relates to a continuous flow micro-total process system for preparation of celecoxib, a COX-2 selective non-steroidal anti-inflammatory drug, and analogs thereof.Type: ApplicationFiled: January 27, 2020Publication date: April 28, 2022Inventors: Srihari Pabbaraja, Ajay Kumar Singh, Vinay Kumar Sthalam
-
Patent number: 11311554Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.Type: GrantFiled: March 25, 2019Date of Patent: April 26, 2022Assignee: SLAYBACK PHARMA LLCInventors: Umangi K. Soni, Prem Prakash Singh, Hanimi Reddy Bapatu, Praveen Kumar Subbappa, Ajay Kumar Singh
-
Publication number: 20210409267Abstract: Techniques for self-service provisioning and activation of cloud services are disclosed. In some embodiments, a self-service user interface is generated through which a cloud service subscriber may input configuration parameters to customize an instance of the cloud service. The configuration parameters may define topology, deployment, and/or operational configurations for the cloud service. Responsive to receiving configuration parameters through the self-service user interface, a set of instructions may be automatically generated and executed to perform one or more provisioning operations.Type: ApplicationFiled: January 12, 2021Publication date: December 30, 2021Applicant: Oracle International CorporationInventors: Lisa Ozlem Ozkan, Weiran Zhao, Srikanth Chittineni, Lawrence Yoo Lindsey, Kanchan Shringi, Ajay Kumar Singh
-
Patent number: 11212171Abstract: Techniques for self-service provisioning and activation of cloud services are disclosed. In some embodiments, a self-service user interface is generated through which a cloud service subscriber may input configuration parameters to customize an instance of the cloud service. The configuration parameters may define topology, deployment, and/or operational configurations for the cloud service. Responsive to receiving configuration parameters through the self-service user interface, a set of instructions may be automatically generated and executed to perform one or more provisioning operations.Type: GrantFiled: January 12, 2021Date of Patent: December 28, 2021Assignee: Oracle International CorporationInventors: Lisa Ozlem Ozkan, Weiran Zhao, Srikanth Chittineni, Lawrence Yoo Lindsey, Kanchan Shringi, Ajay Kumar Singh
-
Publication number: 20210369604Abstract: Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.Type: ApplicationFiled: July 27, 2021Publication date: December 2, 2021Applicant: SLAYBACK PHARMA LLCInventors: Rahul Dhulaji BHISE, Ajay Kumar SINGH, Mahadeo Vasant MAHADIK, Ashish Anilrao DUBEWAR, Molugu Prashanth REDDY
-
Patent number: 11110054Abstract: The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.Type: GrantFiled: October 25, 2018Date of Patent: September 7, 2021Assignee: SLAYBACK PHARMA LLCInventors: Rahul Dhulaji Bhise, Ajay Kumar Singh, Mahadeo Vasant Mahadik, Ashish Anilrao Dubewar, Molugu Prashanth Reddy
-
Patent number: 11103502Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: November 27, 2019Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Patent number: 11103503Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: January 28, 2020Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Publication number: 20210077485Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: November 20, 2020Publication date: March 18, 2021Applicant: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu